The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

The Federal Trade Commission (FTC) released a 60-page report Tuesday targeting the three biggest pharmacy benefit managers (PBMs), claiming the companies hiked the prices of specialty drugs by ...

Margin expansion at Express Scripts, Caremark and Optum Rx increased by $336 million between 2017 and 2021, officials say.

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...